Stockscreener 앱 받기
13.85
1.91%
-0.27
시간 외 거래:
13.80
-0.05
-0.36%
전일 마감가:
$14.12
열려 있는:
$14.34
하루 거래량:
629.53K
Relative Volume:
0.69
시가총액:
$393.66M
수익:
$42.35M
순이익/손실:
$-78.67M
주가수익비율:
-4.9181
EPS:
-2.8161
순현금흐름:
$-63.18M
1주 성능:
-13.60%
1개월 성능:
-10.30%
6개월 성능:
+96.18%
1년 성능:
-31.81%
1일 변동 폭
$13.30
$14.48
1주일 범위
$13.26
$16.55
52주 변동 폭
$5.50
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
13.85 | 393.66M | 42.35M | -78.67M | -63.18M | -2.8161 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $41 - Moomoo
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform - Yahoo Finance
Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade - marketscreener.com
Why Is Arcturus Therapeutics Stock Gaining Thursday? - benzinga.com
Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure - Yahoo Finance
ARCT Upgraded by Citigroup -- Price Target Raised to $20.00 - GuruFocus
ARCT Looks 565.3% Overvalued on GF Value™ - GuruFocus
Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - benzinga.com
Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8 - marketscreener.com
ARCT Maintained by BTIG -- Price Target Lowered to $20 - GuruFocus
Citi Upgrades Arcturus Therapeutics(ARCT.US) to Buy Rating, Raises Target Price to $20 - Moomoo
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics PlatformSlideshow (NASDAQ:ARCT) 2026-09-24 - Seeking Alpha
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - BioSpace
Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update - Kalkine Media
ARCT Looks 521.5% Overvalued on GF Value™ - GuruFocus
Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency - Seeking Alpha
Arcturus Showcases Phase 2 ARCT-810 Data, mRNA Advances - TipRanks
Arcturus Therapeutics Holdings Inc to Host Virtual Presentation Transcript - GuruFocus
Arcturus Therapeutics Holdings Inc. entered into a definitive agreement to acquire MyNeo NV. - marketscreener.com
Arcturus Therapeutics (ARCT) Slips 2.11% to $14.38 as Shares Drift Toward Range SupportInside Day Breakout - siam.in
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT) - Seeking Alpha
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform - Yahoo Finance
ARCT Stock Price and Chart — NASDAQ:ARCT - TradingView
Trading the Move, Not the Narrative: (ARCT) Edition - Stock Traders Daily
Arcturus Therapeutics Holdings Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - Investing.com India
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year By Investing.com - Investing.com Canada
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year - Investing.com
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (ARCT) Peer Comparison – Compare with Others - Value Research
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Why is Arcturus Therapeutics stock surging today? By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com
Arcturus Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (ARCT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcturus Therapeutics (ARCT) Drops 6% as Biotech Sector Headwinds IntensifyFibonacci Fan - dars.gov.et
Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium - TipRanks
Arcturus (ARCT) Results Check: EPS Clears the Reported Estimate; Market Response: Shares Finish 22.38% Up for the Current SessionEarnings Power Value - vinanet.vn
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back - Yahoo Finance
Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):